Gene therapy for prostate cancer

Urology

Volumn 57, Issue 1, 2001, Pages 8-16

  Shalev, Moshe ^a   Thompson, Timothy C ^a   Kadmon, Dov ^a   Ayala, Gustavo ^a   Kernen, Kenneth ^a   Miles, Brian J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; VIRUS VECTOR;

APOPTOSIS; CANCER CELL; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; MALE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SUICIDE GENE;

APOPTOSIS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; MALE; PROSTATIC NEOPLASMS; T-LYMPHOCYTES;

EID: 0035156324     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00903-1     Document Type: Review

References (67)

1. Epidemiology of prostate cancer
2. Oncogenes, growth factors and hormones in prostatic cancer
3. Gene therapy of prostate cancer; p53, suicidal genes and other targets
4. Cationic liposome-mediated gene transfer
5. Gene therapy for prostate cancer
6. Human gene therapy
7. Adenovirus and adeno-associated virus mediated gene transfer
8. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer
9. Vaccinia virus; a tool for research and vaccine development
10. Effect of canary pox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth
11. Gene transfer; a review of methods and applications
12. Viral vector delivery in solid-state vehicles; gene expression in a murine prostate cancer model
13. Intraprostatic interleukin-2 (IL-2) gene therapy; preliminary results of a phase I clinical trial for the treatment of locally advanced prostate cancer
14. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues
15. Inhibition of cell migration, spreading and focal adhesions by tumor suppression PTEN
16. Allelic loss of chromosome 16q and 10q in human prostate cancer
17. Prostate cancer-biology of metastasis and its clinical implications
18. BRCA 1 as a potential human prostate tumor suppressor; modulation of proliferation, damage responses and expression of cell regulatory proteins
19. Evidence for a prostate cancer susceptibility locus on the X chromosome
20. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis
21. Gluthatione transferases; structure, regulations and therapeutic implications
22. Role of the Bcl-2 gene family in prostate cancer progression and its implication for therapeutic intervention
23. Detection of the apoptosis suppressing oncoprotein Bcl-2 in hormone refractory human prostate cancers
24. Expression of the proto-oncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
25. Expression of Bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen-independent prostate cancer
26. Overcoming Bcl-2 and p53-mediated resistance in prostate cancer
27. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model
28. p53 abnormalities in primary prostate cancer; single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA
29. p53 is mutated in a subset of advanced-stage prostate cancer
30. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity
31. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein
32. Genetic determination of p53-induced apoptosis and growth arrest
33. AD-p53 intraprostatic gene therapy preceding radical prostatectomy (RP); an in vivo model for targeted therapy development
34. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation
35. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity
36. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug
37. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53
38. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
39. Gene therapy for lung cancer; enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer
40. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells
41. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate and breast cancer
42. Preoperative p53, Bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy
43. Androgens induce resistance to Bcl-2 mediated apoptosis in LNCaP prostate cancer cells
44. Overexpression of Bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
45. Development of a hammerhead ribozyme against Bcl-2; preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer
46. Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells
47. Bcl-2 is the guardian of microtubule integrity
48. A pilot study of chemohormonal therapy for metastatic prostate cancer
49. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP; overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
50. Immunologic dysfunction in cancer
51. Immunotherapy for prostate cancer in the Dunning rat model; use of cytokine gene modified tumor vaccines
52. Cytokine mediated immune-gene therapy in rat prostate cancer model
53. Induction of immunity to prostate cancer antigens; results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex-vivo gene transfer
54. In situ gene therapy for prostate cancer
55. Ex-vivo gene therapy using cytokine-transduced tumor vaccines; molecular and clinical pharmacology
56. Cancer chemotherapy using suicide genes
57. Establishment and characterization of seven Dunning rat prostatic cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers
58. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models
59. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer
60. In situ gene therapy for adenocarcinoma of the prostate; a phase I clinical trial
61. Suicide gene therapy toxicity after multiple and repeated injections in patients with localized prostate cancer
62. Morphologic changes associated with suicide gene therapy for prostate cancer
63. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells
64. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity
65. Prostate attenuated replication competent adenovirus (ARCA) CN706; a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
66. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer; construction and testing of a tissue-specific adenovirus vector
67. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207